Corticosteroids, An Issue of Rheumatic Disease Clinics of North America, E-Book

 
 
Elsevier (Verlag)
  • 1. Auflage
  • |
  • erschienen am 19. Januar 2016
  • |
  • 100 Seiten
 
E-Book | ePUB mit Adobe DRM | Systemvoraussetzungen
E-Book | PDF mit Adobe DRM | Systemvoraussetzungen
978-0-323-41713-6 (ISBN)
 
Corticosteroids represent the most important and frequently used class of anti-inflammatory and immunosuppressant agents in the management of many rheumatological conditions. Included in this issue will be articles on the following topics: Glucocorticoid use in intra-articular and soft tissue injections, corticosteroids and osteoporosis, corticosteroids in lupus, ANCA associated vasculitis, and many more!
  • Englisch
  • Philadelphia
  • |
  • USA
Elsevier Health Sciences
  • 4,18 MB
978-0-323-41713-6 (9780323417136)
0323417132 (0323417132)
weitere Ausgaben werden ermittelt
  • Front Cover
  • Corticosteroids
  • Copyright
  • Contributors
  • CONSULTING EDITOR
  • EDITOR
  • AUTHORS
  • Contents
  • Foreword: Corticosteroids
  • Preface: Corticosteroids: Friends and Foes
  • The History of Cortisone Discovery and Development
  • Corticosteroids: Mechanisms of Action in Health and Disease
  • Glucocorticoids and Rheumatoid Arthritis
  • Corticosteroids in Lupus
  • Corticosteroids in Lupus Nephritis and Central Nervous System Lupus
  • Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis
  • Corticosteroids in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
  • Corticosteroids in Myositis and Scleroderma
  • Corticosteroids in Sarcoidosis
  • Corticosteroids for Pain of Spinal Origin: Epidural and Intraarticular Administration
  • Infection Risk and Safety of Corticosteroid Use
  • Glucocorticoid-induced Osteoporosis
  • RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
  • FORTHCOMING ISSUES
  • May 2016
  • August 2016
  • November 2016
  • RECENT ISSUES
  • November 2015
  • August 2015
  • May 2015
  • Foreword: Corticosteroids
  • Preface: Corticosteroids: Friends and Foes
  • The History of Cortisone Discovery and Development
  • Key points
  • INTRODUCTION
  • PHILIP SHOWALTER HENCH
  • EDWARD CHARLES KENDALL
  • WORLD WAR II
  • MRS G
  • THE STORY BREAKS
  • THE NOBEL PRIZE
  • AFTERMATH
  • THE EMPIRE STRIKES BACK
  • EPILOGUE
  • THE LEGACY OF CORTICOSTEROIDS
  • REFERENCES
  • Corticosteroids
  • Key points
  • INTRODUCTION
  • GLUCOCORTICOID SYNTHESIS, SECRETION, AND BIOAVAILABILITY
  • GLUCOCORTICOID RECEPTOR
  • MECHANISMS OF GLUCOCORTICOID ACTION
  • Genomic Actions of Glucocorticoids
  • Nongenomic Actions of Glucocorticoids
  • GLUCOCORTICOID RECEPTOR HETEROGENEITY
  • Glucocorticoid Receptor Splice Variants
  • Glucocorticoid Receptor Translational Isoforms
  • Posttranslational Modifications of Glucocorticoid Receptor
  • Glucocorticoid Receptor Polymorphisms
  • SUMMARY AND FUTURE CONSIDERATIONS
  • REFERENCES
  • Glucocorticoids and Rheumatoid Arthritis
  • Key points
  • INTRODUCTION
  • CLINICAL APPLICATIONS IN RHEUMATOID ARTHRITIS
  • Inflammation Under Control
  • Pain Relief and Structural Progression
  • Fatigue, Anxiety, and Depression
  • DOSING IN RHEUMATOID ARTHRITIS
  • Equivalents of Prednisone
  • ADMINISTRATION IN RHEUMATOID ARTHRITIS
  • Systemic
  • Oral
  • Parenteral
  • Intra-articular
  • SIDE EFFECTS
  • Patient Education
  • Minimizing glucocorticoid side effects
  • Osteoporosis and Fractures
  • Other Musculoskeletal Adverse Events
  • Endocrine and Metabolic Adverse Events
  • Glucose metabolism and diabetes
  • Weight gain
  • Hypothalamic-pituitary-adrenal axis suppression
  • Cardiovascular Risk Factors and Atherosclerosis
  • Infections
  • Renal Dysfunction
  • Dermatologic Side Effects
  • Ophthalmologic Side Effects
  • Gastrointestinal Side Effects
  • Neuropsychological Side Effects
  • DRUG-DRUG INTERACTIONS
  • FUTURE CONSIDERATIONS
  • SUMMARY
  • REFERENCES
  • Corticosteroids in Lupus
  • Key points
  • INTRODUCTION
  • CLINICAL APPLICATIONS
  • General
  • Mucocutaneous
  • Musculoskeletal
  • Hematologic
  • Cardiac
  • Pulmonary
  • Gastrointestinal
  • Ophthalmologic
  • Nephritis and Neuropsychiatric
  • Pregnancy and Lactation
  • DOSING
  • Systemic Lupus Erythematosus Pathogenesis
  • Mechanism of Corticosteroids
  • Dosing
  • Resistance to Corticosteroids
  • ADMINISTRATION
  • SIDE EFFECTS
  • Corticosteroids and Damage
  • Corticosteroids and Cardiovascular Disease
  • Corticosteroids and Infections
  • Corticosteroids and Fracture
  • DRUG-DRUG INTERACTIONS
  • PRACTICAL TREATMENT CONSIDERATIONS
  • FUTURE CONSIDERATIONS/SUMMARY
  • REFERENCES
  • Corticosteroids in Lupus Nephritis and Central Nervous System Lupus
  • Key points
  • INTRODUCTION
  • EPIDEMIOLOGY OF LUPUS NEPHRITIS
  • EVALUATION OF LUPUS NEPHRITIS
  • TREATMENT GOALS FOR LUPUS NEPHRITIS
  • PROLIFERATIVE LUPUS NEPHRITIS INDUCTION THERAPY
  • PROLIFERATIVE LUPUS NEPHRITIS MAINTENANCE THERAPY
  • CHALLENGING CURRENT CORTICOSTEROID PRACTICES
  • TAPERING OF CORTICOSTEROIDS
  • EPIDEMIOLOGY OF CENTRAL NERVOUS SYSTEM LUPUS
  • EVALUATION OF CENTRAL NERVOUS SYSTEM LUPUS
  • COMMON CENTRAL NERVOUS SYSTEM FEATURES IN PATIENTS WITH LUPUS
  • FEATURES OF LESS FREQUENT CENTRAL NERVOUS SYSTEM LUPUS EVENTS
  • TREATMENT STRATEGIES FOR CENTRAL NERVOUS SYSTEM LUPUS
  • IMMUNOSUPPRESSION FOR CENTRAL NERVOUS SYSTEM LUPUS REFRACTORY TO CORTICOSTEROIDS
  • ADVERSE EFFECTS OF CORTICOSTEROIDS
  • SUMMARY
  • REFERENCES
  • Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis
  • Key points
  • INTRODUCTION
  • CLINICAL FEATURES
  • MANAGEMENT
  • GLUCOCORTICOIDS FOR TREATMENT OF POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS
  • MECHANISMS OF GLUCOCORTICOID ACTIONS
  • WHY DOES CLINICAL EFFICACY OF GLUCOCORTICOID THERAPY VARY AMONG DIFFERENT PATIENTS?
  • ADVERSE EFFECTS OF GLUCOCORTICOIDS
  • CLINICAL ASPECTS OF THERAPY WITH GLUCOCORTICOIDS IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS
  • Polymyalgia Rheumatica
  • Giant Cell Arteritis
  • NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND ANALGESICS IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS
  • GLUCOCORTICOID-SPARING AGENTS IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS
  • Nonbiological Agents
  • Biological Agents
  • ASPIRIN USE IN GIANT CELL ARTERITIS
  • MANAGEMENT OF GLUCOCORTICOID-RELATED COMPLICATIONS IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS
  • SUMMARY
  • REFERENCES
  • Corticosteroids in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
  • Key points
  • INTRODUCTION
  • REMISSION INDUCTION THERAPY
  • Intravenous Glucocorticoids
  • Oral Glucocorticoids
  • MAINTENANCE THERAPY
  • TREATMENT OF RELAPSES
  • LOCAL GLUCOCORTICOIDS
  • FUTURE CONSIDERATIONS
  • SUMMARY
  • REFERENCES
  • Corticosteroids in Myositis and Scleroderma
  • Key points
  • IDIOPATHIC INFLAMMATORY MYOPATHIES
  • Background and Clinical Manifestations
  • Diagnostic Evaluation
  • Classification Criteria for Idiopathic Inflammatory Myopathy
  • Treatment Options
  • POLYMYOSITIS
  • Background and Clinical Manifestations
  • Diagnostic Evaluation
  • Treatment
  • Corticosteroids
  • Corticosteroid-sparing options
  • DERMATOMYOSITIS
  • Background and Clinical Manifestations
  • Diagnostic Evaluation
  • Treatment
  • Corticosteroids
  • Corticosteroid-sparing options
  • INCLUSION BODY MYOSITIS
  • Background and Clinical Manifestations
  • Diagnostic Evaluation
  • Treatment
  • Corticosteroids
  • Corticosteroid-sparing options
  • NECROTIZING MYOPATHIES
  • Background and Clinical Presentation
  • Diagnostic Evaluation
  • Treatment
  • Corticosteroids
  • Corticosteroid-sparing options
  • SCLERODERMA: LOCALIZED SCLERODERMA (MORPHEA) AND SYSTEMIC SCLEROSIS
  • LOCALIZED SCLERODERMA (MORPHEA)
  • Background and Clinical Manifestations
  • Diagnostic Evaluation
  • Treatment
  • Corticosteroids
  • Corticosteroid-sparing options
  • SYSTEMIC SCLEROSIS
  • Background and Clinical Presentation
  • Diagnostic Evaluation
  • Treatment
  • Skin
  • Corticosteroids
  • Corticosteroid-sparing options
  • Musculoskeletal
  • Corticosteroids
  • Corticosteroid-sparing options
  • Interstitial lung disease
  • Corticosteroids
  • Corticosteroid-sparing options
  • Scleroderma renal crisis
  • SUMMARY
  • REFERENCES
  • Corticosteroids in Sarcoidosis
  • Key points
  • INTRODUCTION
  • INDICATIONS TO TREAT SARCOIDOSIS
  • GENERAL APPROACH TO THE TREATMENT OF SARCOIDOSIS WITH CORTICOSTEROIDS
  • Issues of Dose
  • Issues of Duration
  • Issues of When to Add Additional Agents to Corticosteroids
  • CORTICOSTEROID THERAPY FOR SPECIFIC FORMS OF SARCOIDOSIS
  • Pulmonary Sarcoidosis
  • Cardiac Sarcoidosis
  • Skin Sarcoidosis
  • Eye Sarcoidosis
  • Neurologic
  • Musculoskeletal Involvement
  • Other Organs
  • SUMMARY
  • REFERENCES
  • Corticosteroids for Pain of Spinal Origin
  • Key points
  • INTRODUCTION
  • BACKGROUND
  • THERAPEUTIC RATIONALE
  • CLINICAL INDICATIONS
  • ANATOMIC TARGETS FOR CORTICOSTEROID INJECTION
  • EPIDURAL STEROID INJECTION
  • Epidural Steroid Injection: Three Approaches
  • Epidural Steroid Injection: Efficacy
  • Epidural Steroid Injection: Dosage
  • Epidural Steroid Injection: Fluoroscopy
  • LOCAL INJECTION FOR CHRONIC LOW BACK PAIN SYNDROMES ATTRIBUTED TO THE LUMBAR FACET JOINTS
  • SACROILIAC JOINT INJECTION
  • Comment: Area of Overlap - Spinal Injections into Facet/Sacroiliac Joints Related to Discussion in Other Chapters About Int ...
  • Complications
  • SIDE EFFECTS OF THE STEROIDS
  • Complications: Dosage
  • Complications: Steroid Formulation
  • Complications: Needle Placement
  • ORAL STEROIDS
  • Contraindications
  • REFERENCES
  • Infection Risk and Safety of Corticosteroid Use
  • Key points
  • INTRODUCTION
  • INFECTION IN RHEUMATIC DISEASES AND CORTICOSTEROIDS
  • RANDOMIZED CONTROLLED TRIALS
  • OBSERVATIONAL STUDIES
  • OPPORTUNISTIC INFECTIONS
  • PNEUMOCYSTIS JIROVECI PNEUMONIA
  • Herpes Zoster
  • Strongyloidiasis
  • Tuberculosis
  • VACCINATION AND OTHER PREVENTION STRATEGIES
  • Pneumocystis jiroveci Pneumonia
  • Herpes Zoster
  • Tuberculosis
  • SUMMARY
  • REFERENCES
  • Glucocorticoid-induced Osteoporosis
  • Key points
  • INTRODUCTION
  • GLUCOCORTICOID EFFECTS ON BONE
  • EPIDEMIOLOGY
  • DIAGNOSIS/IDENTIFYING PATIENTS AT RISK
  • Bone Mineral Density Measurement
  • FRAX
  • Other Testing Strategies
  • PREVENTION AND TREATMENT
  • Lifestyle Measures and Assessment
  • Calcium and Vitamin D
  • Bisphosphonates
  • Teriparatide
  • Denosumab
  • Raloxifene
  • Percutaneous Vertebroplasty
  • International Guidelines for Glucocorticoid-induced Osteoporosis
  • Postmenopausal women and men greater than or equal to 50 years of age
  • Premenopausal women and men aged less than 50
  • SUMMARY
  • ACKNOWLEDGMENTS
  • REFERENCES
  • Index

Dateiformat: EPUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat EPUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Dateiformat: PDF
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

73,77 €
inkl. 19% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe DRM
siehe Systemvoraussetzungen
PDF mit Adobe DRM
siehe Systemvoraussetzungen
Hinweis: Die Auswahl des von Ihnen gewünschten Dateiformats und des Kopierschutzes erfolgt erst im System des E-Book Anbieters
E-Book bestellen

Unsere Web-Seiten verwenden Cookies. Mit der Nutzung dieser Web-Seiten erklären Sie sich damit einverstanden. Mehr Informationen finden Sie in unserem Datenschutzhinweis. Ok